Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 7/20 | 0.59 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477036 | 1.00 | CSNK1E (0.59) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477117 | 0.91 | CSNK1E (0.56) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477096 | 0.91 | CSNK1E (0.56) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477095 | 0.91 | CSNK1E (0.56) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477157 | 0.90 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477156 | 0.90 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477009 | 0.89 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477016 | 0.89 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477007 | 0.89 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 | |
| SCHEMBL477110 | 0.89 | CSNK1E (0.55) | CSNK1ENMT1PRKCQPRKCDACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | claimed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | claimed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | claimed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | claimed |
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | NR3C1, CNKSR1, NR3C2 | CSNK1E 2760/4885NMT1 4192/4885PRKCQ 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.